Cladribine, Cytarabine and Venetoclax for HR-MDS

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
60 patients (estimated)
Sponsors
MD Anderson Cancer Center
Tags
Antimetabolites, BCL-2 Inhibitor, Chemotherapy, Hypomethylating Agents (HMA)
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1495
NCT Identifier
NCT05365035

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.